Evidence map›Paper›PMID 42299122›Full record

ArticleAnnals of medicine2026

Investigating the efficacy and safety of bronchoscopic removal of aspergilloma in PTB-CCPA.

Hua Li, Haihao Xiao, Weiming Fang, Duohua Su, Tianyi Li, Yu Li, Ling Zhang, Wenjie Su, Ling Wu, Jiahua Chen and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Hua LiState Key Laboratory of Respiratory Disease, Instiute of Tuberculosis, Guangzhou Medical University, Guangzhou Chest Hospital Affiliated to Guangdong Pharmaceutical University, Guangzhou, China.
Haihao XiaoState Key Laboratory of Respiratory Disease, Instiute of Tuberculosis, Guangzhou Medical University, Guangzhou Chest Hospital Affiliated to Guangdong Pharmaceutical University, Guangzhou, China.
Weiming FangState Key Laboratory of Respiratory Disease, Instiute of Tuberculosis, Guangzhou Medical University, Guangzhou Chest Hospital Affiliated to Guangdong Pharmaceutical University, Guangzhou, China.
Duohua SuState Key Laboratory of Respiratory Disease, Instiute of Tuberculosis, Guangzhou Medical University, Guangzhou Chest Hospital Affiliated to Guangdong Pharmaceutical University, Guangzhou, China.
Tianyi LiState Key Laboratory of Respiratory Disease, Instiute of Tuberculosis, Guangzhou Medical University, Guangzhou Chest Hospital Affiliated to Guangdong Pharmaceutical University, Guangzhou, China.
Yu LiState Key Laboratory of Respiratory Disease, Instiute of Tuberculosis, Guangzhou Medical University, Guangzhou Chest Hospital Affiliated to Guangdong Pharmaceutical University, Guangzhou, China.
Ling ZhangState Key Laboratory of Respiratory Disease, Instiute of Tuberculosis, Guangzhou Medical University, Guangzhou Chest Hospital Affiliated to Guangdong Pharmaceutical University, Guangzhou, China.
Wenjie SuState Key Laboratory of Respiratory Disease, Instiute of Tuberculosis, Guangzhou Medical University, Guangzhou Chest Hospital Affiliated to Guangdong Pharmaceutical University, Guangzhou, China.
Ling WuState Key Laboratory of Respiratory Disease, Instiute of Tuberculosis, Guangzhou Medical University, Guangzhou Chest Hospital Affiliated to Guangdong Pharmaceutical University, Guangzhou, China.
Jiahua ChenState Key Laboratory of Respiratory Disease, Instiute of Tuberculosis, Guangzhou Medical University, Guangzhou Chest Hospital Affiliated to Guangdong Pharmaceutical University, Guangzhou, China.
Yi XieState Key Laboratory of Respiratory Disease, Instiute of Tuberculosis, Guangzhou Medical University, Guangzhou Chest Hospital Affiliated to Guangdong Pharmaceutical University, Guangzhou, China.
Yikai XieState Key Laboratory of Respiratory Disease, Instiute of Tuberculosis, Guangzhou Medical University, Guangzhou Chest Hospital Affiliated to Guangdong Pharmaceutical University, Guangzhou, China.
Dehu PengState Key Laboratory of Respiratory Disease, Instiute of Tuberculosis, Guangzhou Medical University, Guangzhou Chest Hospital Affiliated to Guangdong Pharmaceutical University, Guangzhou, China.
Ning SuState Key Laboratory of Respiratory Disease, Instiute of Tuberculosis, Guangzhou Medical University, Guangzhou Chest Hospital Affiliated to Guangdong Pharmaceutical University, Guangzhou, China.
Jinxing HuGuangzhou Eighth People's Hospital, Guangzhou, P. R. China.
Yanbin ZhangGuangzhou Red Cross Hospital, Guangzhou, P. R. China.
Chunmei TangState Key Laboratory of Respiratory Disease, Instiute of Tuberculosis, Guangzhou Medical University, Guangzhou Chest Hospital Affiliated to Guangdong Pharmaceutical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGiven high symptom recurrence rates after discontinuation of antifungal therapy (AF), a comparison was made between AF alone and in combination with bronchoscopic aspergilloma removal (BRA) for treating post-tuberculosis chronic cavitary pulmonary aspergillosis (PTB-CCPA) patients, focusing on fungal ball clearance rate, relapse rate, and relapse risk factors.

methodsThis retrospective cohort study was conducted at Guangzhou Chest Hospital, China, from January 2014 to December 2021, with follow-up through October 2023. Patients with PTB-CCPA who met diagnostic criteria (cavitary tuberculosis history, CT-confirmed fungal balls, and microbiological/serological

resultsThe enrolled patients were divided into two groups: the control group (32 patients, 36.4%) received only AF, and the treatment group (56 patients, 63.6%) received a combination of AF and BRA (AF+BRA). The aspergilloma clearance rate in the cavity was 14.8% in the AF group and 100% in the AF+BRA group (

conclusionsAF+BRA can eliminate Aspergillus fungal balls, may cure PTB-CCPA, shorten antifungal treatment duration, and reduce recurrence and mortality, suggesting that it is a superior treatment approach.

Indexed as

Antifungal AgentsBronchoscopyPulmonary AspergillosisTuberculosis, PulmonaryAdultAgedChinaCombined Modality TherapyFemaleHumansKaplan-Meier EstimateMaleMiddle AgedRecurrenceRetrospective StudiesRisk FactorsAntifungal AgentsAntifungal therapybronchoscopic removal aspergillomapost-tuberculosis chronic cavitary pulmonary aspergillosis

Identifiers

PMID42299122
PMCPMC13274504

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.